Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
About the study
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
Diagnosis of Familial Partial Lipodystrophy (FPLD)
EXCLUSION CRITERIA
Exclusion Criteria:
Previous treatment with metreleptin
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Partial Lipodystrophy
Age (in years)
12+
Phase
Phase 3
Participants needed
65
Est. Completion Date
Jan 31, 2026
Treatment type
Interventional
Sponsor
Amryt Pharma
ClinicalTrials.gov identifier
NCT05164341
Study number
APG-20
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?